Roche Holding AG Chairman Severin Schwan accused the US government of using heavy-handed tactics over drug prices and warned it could have a negative long-term impact on Europe.
The Swiss drug company agreed a pact with President Donald Trump’s administration to lower drug prices for some Americans in late 2025, in exchange for a three-year reprieve from threatened tariffs. Roche was one of several pharma companies that made similar pledges after being targeted by Trump’s Most Favored Nation (MFN) drug pricing policy.